newsfilter
← Latest News
Business Wire·

Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference

  • Contineum Therapeutics (NASDAQ: CTNM) announced management will present at the 2026 Goldman Sachs Global Healthcare Conference on Tuesday, June 9th at 1:20 p.m. ET.
  • An audio webcast of the fireside chat will be accessible on the Investors section of Contineum's website, with a replay also available.
  • The company is a clinical-stage biopharmaceutical firm developing novel, oral small molecule therapies for neuroscience, inflammation & immunology indications.
  • PIPE-791, an LPA1 receptor antagonist, is in clinical development for idiopathic pulmonary fibrosis & chronic pain.
  • PIPE-307, a selective M1 receptor inhibitor, is in clinical development for relapsing-remitting multiple sclerosis & major depressive disorder.
  • Steve Kunszabo serves as Senior Director, Investor Relations & Corporate Communications for Contineum Therapeutics.